NEW YORK (GenomeWeb) – Luminex President and CEO Nachum Shamir said today that the firm believes it will report fiscal year 2016 revenues at the high end of its guidance range of $247 million to $255 million.
Speaking at the Jefferies 2016 Global Healthcare Conference held here, Shamir discussed the multiple growth drivers for the company including the recent launch of its Aries real-time PCR-based sample-to-answer molecular diagnostics system and its impending acquisition of Nanosphere.